Amcenestrant study on hold due to Sanofi trial failure
Sanofi has halted further development of amcenestrant, a treatment once thought to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company’s development prospects.
Natco Pharma receives preliminary approval for generic Yondelis
The US Food and Drug Administration has tentatively approved Natco Pharma’s Abbreviated New Drug Application (ANDA) for 1mg/vial trabectedin for injection (generic for Yondelis).
Piramal, Cadila among 32 companies bidding for Sharon Bio-Medicine
Piramal Pharma, Cadila Pharmaceuticals, Shamrock Pharmachemi, and ACG Associated Capsules are a few of the 32 companies competing to acquire Sharon Bio-Medicine, which is going through a second round of insolvency proceedings.
Sun Pharma's US business may exceed $2 billion by 2025 due to specialty drugs
Sun Pharmaceutical Industries’ US business will surpass $2 billion in revenue by 2025, owing to its specialty drug portfolio. The Mumbai-based company is currently conducting clinical trials for four specialty medications.
First Zantac lawsuit plaintiff withdraws case before trial
According to attorney and the drugmakers named as defendants, the plaintiff in the initial lawsuit involving the heartburn medication Zantac that is scheduled for trial has decided to withdraw the claim.
Codagenix receives US Department of Defense Award for development of Dengue Vaccine
Codagenix announced a $4.4 million award from the Department of Defense to advance development of CodaVax-DENV, its next generation tetravalent dengue vaccine candidate.
Aytu BioPharma received US patent for enzastaurin
Aytu BioPharma announced that the US
Patent and Trademark Office has issued a
new patent for AR101/Enzastaurin for the
targeted epigenetic therapy of inherited
aortic aneurysm and other diseases.
